No Data
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Raises Target Price to $49
Tourmaline Bio's Promising Clinical Developments and Financial Stability Underpin Buy Rating
Express News | Tourmaline Bio Inc Files for Mixed Shelf of up to $350 Mln - SEC Filing
Talaris Therapeutics GAAP EPS of -$0.78 Beats by $0.05
Tourmaline Bio | 10-Q: Q3 2024 Earnings Report
Tourmaline Bio Q3 2024 GAAP EPS $(0.78) Beats $(0.84) Estimate, Cash, Cash Equivalents And Investments Of $314.4M, Providing Cash Runway Into 2027
No Data
No Data